Time for India to be firm with drugmakers rather than deregulate

Lax stance risks opportunity for 'friend-shoring' to serve Western nations

Avatar
20230131 Serum Institute of India.jpg

Employees pack boxes containing vials of Covishield coronavirus vaccine at the Serum Institute of India in Pune in November 2021: New Delhi should seek to amend the constitution and consolidate drug regulation at a national level.  © AP

Akhil Ramesh is a research fellow at the Pacific Forum, a foreign policy research institute based in Honolulu, Hawaii.

At a time when the U.S. and European nations are becoming anxious about the dependence of their supply chains on China for the production of medicines and drugs, India's vast pharmaceutical industry should be just the cure.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.